Navigation Links
Data Show Common Allergy Tests Are Not Interchangeable

- Results Vary Widely Compared to Established Clinical Standards Using

ImmunoCAP -

PORTAGE, Mich., May 8 /PRNewswire/ -- Data published in the May issue of the Journal of Allergy and Clinical Immunology revealed variations in the results of three common allergy diagnostic blood tests used to quantify sensitivities to allergens. The study, conducted by allergy specialists at Mount Sinai School of Medicine, determined that the laboratory results from two other commercial tests for specific IgE were not equivalent to those measured by ImmunoCAP(R) Specific IgE blood test.

Previously published studies from thought-leading allergists have established threshold values for many food allergens. These values are often used to guide decisions about the severity of a patient's food allergy and subsequent management strategies. These published data are based upon values determined using ImmunoCAP technology, which have become well-established.

"Test results from the three different specific IgE assays are not interchangeable. This study underscores the importance of knowing which test is being used to generate the patient's results, particularly with food allergies, which can be life-threatening," said Robert Reinhardt, MD, professor of family medicine for Michigan State University College of Human Medicine and U.S. Medical Affairs Director, Phadia U.S. Inc.

Specific IgE is produced in the blood as a result of sensitization to an allergen and typically increases with exposure to that substance. High concentrations of food-specific IgE levels are predictive of a food-induced allergic reaction. These ImmunoCAP derived values provide a quantitative assessment of allergen-specific IgE antibody, helping clinicians determine the severity of an allergy and guide patient management strategies.

The assays used in this study included ImmunoCAP, Turbo-MP (Agilent Technologies offered by LabCorp (Laboratory Corporation of America)) and 3gAllergy Universal Module (Siemens' Immulite(R) system). The tests measured specific IgE levels in 50 patients for egg, milk, peanut, cat, birch and dust mite. The results revealed significant differences among the three tests in the measurement of allergen-specific IgE levels, which can impact the clinical decision-making process.

When quantitative evaluation was performed, the Turbo-MP overestimated IgE levels for egg but underestimated levels for dust mite and birch pollen. Differences also were found between Turbo-MP and ImmunoCAP for milk, peanut and cat. The 3gAllergy Universal Module overestimated all allergen-specific IgE levels compared with ImmunoCAP.

"Results from these tests are used to guide treatment decisions, and variability around the decision points can alter clinical management of a suspected allergy," concluded the study authors. "Food allergen avoidance on the basis of inconsistent laboratory results can have profound nutritional and social implications and can significantly affect a child and the child's family's quality of life."

Another study published in the Annals of Allergy, Asthma & Immunology in July 2007 demonstrated that the ImmunoCAP Specific IgE system was directly traceable to the World Health Organization (WHO) standard preparation for total IgE in the detection of quantitative specific IgE antibodies. This traceability to the WHO standard was not equally demonstrated with the Turbo-RAST and 3gAllergy Universal Module specific IgE assays. The study was the first of its kind to compare specific IgE results of different technologies as measured against an independently verified IgE standard.

"These studies further validate ImmunoCAP's overall performance as compared to other specific IgE allergy blood tests, making it a valuable option in the management of allergic disorders," said Michael Land, president and general manager, Phadia U.S. Inc. "Physicians and patients need to be aware that not all allergy blood tests are the same, and here is a study that concludes that interchanging results can put children at unnecessary risk."

Phadia AB, headquartered in Uppsala, Sweden, is the world leader in in vitro IgE diagnostic research and product development. Its U.S. affiliate is in Portage, Michigan. For more information, call Phadia Customer Service at 1-800-346-4364.

SOURCE Phadia U.S. Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Common Medications Could Cause Physical Impairment in the Elderly
2. Commonly used medications associated with impaired physical function in older adults
3. NHP Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
4. Pennsylvania Pharmacy Carve-out Poses Risks for Commonwealths Neediest Citizens and Taxpayers, National Organization Testifies
5. Delusions Common in Pediatric ICU
6. Daily aspirin may reduce risk of common type of breast cancer
7. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
8. Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence
9. Common Chemotherapy Drug Linked to Memory Problems
10. Obesity, inactivity as common among cancer survivors as rest of Canadians, study shows
11. Common Medications May Harm Memory in Older People
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... The American ... campaign in honor of World AIDS Day 2015. On Nov. 30, ASCP shared its ... public awareness about World AIDS Day and the importance of getting tested for HIV. ...
(Date:11/30/2015)... ... 30, 2015 , ... According to RF Safe, the November ... at Consumer Reports as supporting a “A Call for Clarity” on cell phone ... original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
(Date:11/30/2015)... , ... November 30, 2015 , ... While powdered supplements ... in wasted time. Fortunately, an inventor from Chesterfield, Va., has found an easy to ... keep the scoop used to measure powdered contents in a canister or other container ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... suite of automated breast density assessment and enterprise analytics solutions, here at ... 4, 2015 (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BOSTON , November 30, 2015 /PRNewswire/ ... potential new medicines directed at up to 10 G ... --> PFE ) to research and develop potential ... receptor (GPCR) targets across multiple therapeutic areas. --> ... discovery and development company and wholly-owned subsidiary of Sosei ...
(Date:11/29/2015)... Nov. 29, 2015  Strengthening its leadership in connected ... PHIA) today announced IntelliSpace Portal 8.0 , the ... visualization platform that helps radiologists detect, diagnose and follow-up ... Radiological Society of North America Annual Meeting (RSNA) ... 8.0 helps address the changing demands in radiology that ...
(Date:11/29/2015)... 2015   National Decision Support Company (NDSC) continues ... including notable statewide implementations. As a result, ordering ... Select, more than 1 million times per month—all ... Select provides real-time feedback on the most appropriate ... been implemented at over 100 healthcare systems nationally, ...
Breaking Medicine Technology: